Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Aschan

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Clinical Transplants|January 1, 1990
Allogeneic bone marrow transplantations at Huddinge Hospital and strategies to improve survivalO Ringdén, J Aschan, L Boström, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacologyM Hassan, G Oberg, A N Bekassy, et al.
Transplantation|December 10, 1998
Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipientsP Ljungman, J Aschan, I Lewensohn-Fuchs, et al.
Blood|July 15, 1994
Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantationP Ljungman, I Lewensohn-Fuchs, V Hammarström, et al.
Bone Marrow Transplantation|December 12, 2002
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioningM Hassan, C Nilsson, Z Hassan, et al.
Bone Marrow Transplantation|January 23, 2002
A graft-versus-colonic cancer effect of allogeneic stem cell transplantationH Zetterquist, P Hentschke, A Thörne, et al.
Bone Marrow Transplantation|November 25, 1998
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysisS Carlens, O Ringdén, M Remberger, et al.
Journal of Internal Medicine|February 26, 2013
A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantationO Ringdén, T Erkers, J Aschan, et al.
Blood|September 6, 2001
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donorsM Remberger, O Ringdén, I W Blau, et al.
Annals of Hematology|May 6, 2004
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantationJ Casper, W Knauf, I Blau, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Clinical Transplants|January 1, 1990
Allogeneic bone marrow transplantations at Huddinge Hospital and strategies to improve survivalO Ringdén, J Aschan, L Boström, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacologyM Hassan, G Oberg, A N Bekassy, et al.
Transplantation|December 10, 1998
Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipientsP Ljungman, J Aschan, I Lewensohn-Fuchs, et al.
Blood|July 15, 1994
Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantationP Ljungman, I Lewensohn-Fuchs, V Hammarström, et al.
Bone Marrow Transplantation|December 12, 2002
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioningM Hassan, C Nilsson, Z Hassan, et al.
Bone Marrow Transplantation|January 23, 2002
A graft-versus-colonic cancer effect of allogeneic stem cell transplantationH Zetterquist, P Hentschke, A Thörne, et al.
Bone Marrow Transplantation|November 25, 1998
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysisS Carlens, O Ringdén, M Remberger, et al.
Journal of Internal Medicine|February 26, 2013
A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantationO Ringdén, T Erkers, J Aschan, et al.
Blood|September 6, 2001
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donorsM Remberger, O Ringdén, I W Blau, et al.
Annals of Hematology|May 6, 2004
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantationJ Casper, W Knauf, I Blau, et al.
Pageof 7